Portfolio

I am an author or acknowledged contributor on 70+ peer-reviewed publications spanning a broad range of therapy areas and publication types — from original research papers and systematic reviews to congress abstracts and plain language summaries.

A selection is listed below. Please note that the majority of my work is confidential and cannot be shared publicly.

AUTOIMMUNE DISEASE
  • Bangert C, et al. Long-term use of tralokinumab in patients with atopic dermatitis: A real-world multicentric case series. Int J Dermatol 2025; Online ahead of print.
  • Tanaka Y, et al. Impact of quality of life on overall work productivity impairment and activity impairment of patients with systemic lupus erythematosus: the PEONY study. Lupus Sci Med 2025; 12(1):e001291.
  • Fossati C, et al. Single-centre experience with tralokinumab in dupilumab-experienced and naive patients with atopic dermatitis. J Eur Acad Dermatol Venereol 2024; 39(2):e184–186.
  • Day K, et al. Addressing educational gaps through multidisciplinary team education in eosinophilic oesophagitis management. J CME 2023; 12:223033
  • Tanaka Y, et al. The management of women of child-bearing age with rheumatoid arthritis: an expert report. Expert Rev Clin Immunol 2023; 19:655-669.
  • Changing the way babies eat: Supporting early allergen feeding around the world. EMJ 2022; 7:33-41.
  • Sabet A, et al. A randomised controlled trial comparing the pharmacokinetics and tolerability of the proposed adalimumab biosimilar MSB11022 delivered via autoinjector and pre-filled syringe in healthy subjects. Rheumatol Ther 2022; 9:693-704.
  • Peyrin-Biroulet L, et al. Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues. Therap Adv Gastroenterol 2021; 14:17562848211059954.
  • Taylor PC, et al. The key comorbidities in patients with rheumatoid arthritis: a narrative review. J Clin Med 2021; 10(3):509.
  • Hercogová J, et al. AURIEL‐PsO: a randomized, double‐blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate‐to‐severe chronic plaque‐type psoriasis. Br J Dermatol 2020; 182:316-26.
  • Edwards C, et al. Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis. Clin Rheumatol 2019; 38:3381-3390.
  • Hercogová J, et al. Safety, immunogenicity, and efficacy after a single switch from reference adalimumab to the proposed biosimilar MSB11022: Long-term results from a randomized, double-blind, 52-week, phase III study in moderate-to-severe plaque-type psoriasis patients. Presented at the American Academy of Dermatology Annual Meeting 2019.
  • Baumgart DC, et al. Biological therapies in immune-mediated inflammatory diseases: Can biosimilars reduce access inequities? Front Pharmacol 2019; 10:279.
  • Edwards CJ, et al. Switching to biosimilars: Current perspectives in immune-mediated inflammatory diseases. Expert Opin Biol Ther 2019; 19:1001-14.
HAEMOPHILIA
  • Realising the Promise of Gene Therapy for Haemophilia: Current Status and Future Innovations. EMJ 2023; 11[1]:2-11.
  • Gene therapy in haemophilia: Updates from clinical trials and insights to future technologies. EMJ 2022; 10[5]:2-12.
  • Klamroth R, et al. Illustrative cases from the pathfinder clinical trials of patients with hemophilia A treated with turoctocog alfa pegol (N8-GP). Pat Pref Adher 2021; 15: 2443-54.
ONCOLOGY
  • Peyrottes A, et al. Relugolix in prostate cancer therapy. Clinical evidence and practical considerations. Fr J Urol 2025;35(9):102934.
  • Payne H, et al. Patients’ perceptions and preferences on their choice of androgen deprivation therapy for prostate cancer management in the United Kingdom. Trends Urol Mens Health 2025; 16:e12004.
  • Köhler B, et al. A new biomarker panel for differential diagnosis of cholangiocarcinoma: Results from an exploratory analysis. Int J Biol Markers 2024; 39:107-17.
  • Zhao C, et al. Opportunities and challenges for human papillomavirus vaccination in China. Hum Vaccin Immunother 2024; 20:2329450.
  • Gnant M, et al. Assessing knowledge, competence, and performance following web-based education on early breast cancer management: Healthcare professional questionnaire study and anonymized patient records analysis. JMIR Form Res 2024; 8:e50931.
  • Muley T, et al. Prognostic value of tumor markers ProGRP, NSE and CYFRA 21-1 in patients with small cell lung cancer and chemotherapy-induced remission. Tumor Biology 2024;46:S219-232.
  • Xia L, et al. Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study. Int J Gynecologic Cancer 2023; 33(12)1861-8.
  • Xu Y, et al. Safety and efficacy of atezolizumab in Chinese patients with previously treated locally advanced or metastatic non-small cell lung cancer. An open-label, single-arm, multicentre study. Lung Cancer 2023; 183:107288.
  • Management of thrombosis in high-risk patients: Focus on cancer-associated thrombosis. EMJ 2022; 7[3]:30-39.
  • Gibbs H, Klok FA. New developments, data, and guideline updates: Direct oral anticoagulants for the treatment of venous thromboembolism associated with cancer – interviews with key opinion leaders. EMJ 2022; 10(Suppl 3):2-8.
  • Hock AK, Vigneron A, Carter S, et al. Regulation of p53 stability and function by the deubiquitinating enzyme USP42. EMBO J 2011; 30:4921-30.
  • Stindt MH, Carter S, et al. MDM2 promotes SUMO-2/3 modification of p53 to modulate transcriptional activity. Cell Cycle 2011; 10:3176-88.
  • Carter S and Vousden KH. Modifications of p53: competing for the lysines. Curr Opin Genet Dev 2009; 19:18-24.
  • Carter S and Vousden KH. p53-Ubl fusions as models of ubiquitination, sumoylation and neddylation of p53. Cell Cycle 2008; 7:2519-28.
  • Carter S and Vousden KH. A role for Numb in p53 stabilization. Genome Biol 2008; 9:221.
  • Carter S, et al. C-terminal modifications regulate MDM2 dissociation and nuclear export of p53. Nature Cell Biol 2007; 9:428-35.
  • Carter S, et al. The met receptor degradation pathway: requirement for Lys48-linked polyubiquitin independent of proteasome activity. J Biol Chem 2004; 279:52835-9.
  • Hammond DE, Carter S, et al. Met receptor dynamics and signalling. Curr Top Microbiol Immunol 2004; 286:21-44.
  • Hammond DE, Carter S, et al. Endosomal dynamics of Met determine signaling output. Mol Biol Cell 2003; 14: 1346-54.
CARDIOVASCULAR AND METABOLIC DISEASES
  • Dimmeler S, et al. Translation of genomics into routine cardiological practice: insights from a European Society of Cardiology Cardiovascular Round Table. Eur Heart J 2025;46(15):1384-93.
  • Mahaffey K, et al. Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial. Eur Heart J 2025; 46(12):1096-108.
  • Verma S, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT): Outcomes by sex. J Am Coll Cardiol 2024; 84(17):1678-82.
  • Gabe MBN, et al. Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial. Diabetes Obes Metab 2024; 26(10):4480–89.
  • Mu Y, et al. Efficacy and safety of once weekly semaglutide 2.4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial. Lancet Diabetes Endocrinol 2024; 12:184-195.
  • Umemura I, et al. Relationship between left ventricular ejection fraction and treatment characteristics in hospitalized patients with heart failure – A Japanese database analysis. Circ Rep 2023; 5(10):392-402.
  • Okemah J, et al. Impact on knowledge, competence and performance of a faculty-led web-based educational activity for type 2 diabetes and obesity: Questionnaire study among health care professionals and analysis of anonymized patient records. JMIR Form Res 2023; 7:e49115.
  • Mu Y, et al. Efficacy and safety of once weekly semaglutide 2.4 mg for weight management in a predominantly Asian population with overweight or obesity in the STEP 7 randomised clinical trial. Presented at the 30th European Congress on Obesity, 17-20 May 2023.
  • Suzuki S, et al. Clinical phenotypes of older adults with non-valvular atrial fibrillation not treated with oral anticoagulants by hierarchical cluster analysis in the ANAFIE Registry. PLoS ONE 2023; 18(2): e0280753.
  • Harris SB, et al. The educational impact of online, faculty-led continuing medical education programs in type 2 diabetes: An analysis of changes in the knowledge, competence, and performance of healthcare professionals. JMIR Med Educ 2022; 8(4): e40520.
  • Nguyen-Thi H-Y, et al. Cost-effectiveness of gliclazide-based intensive glucose control vs. standard glucose control in type 2 diabetes mellitus. An economic analysis of the ADVANCE trial in Vietnam. Front Public Health 2020; 8:56203.
  • Klein H and Boleckova J. Resource utilization and procedure-related costs associated with transfemoral transcatheter aortic valve replacement. J Med Econ 2017; 20:640-45.
  • Hinchliffe E, Carter S, et al. Quantitation of aldosterone in human plasma by ultra high performance liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2013; 15:913-914.
  • Carter S, et al. A liquid chromatography tandem mass spectrometry assay for plasma renin activity using online solid-phase extraction. Ann Clin Biochem 2012; 49:570-9.
INFECTIOUS DISEASES
  • Kirste I, et al. Quantifying the vaccine-induced humoral immune response to spike-receptor binding domain as a surrogate for neutralization testing following mRNA-1273 (Spikevax) vaccination against COVID-19. Infect Dis Ther 2023; 12:177-191.
  • Taffertshofer K, et al. Design and performance characteristics of the Elecsys Anti-SARS-CoV-2 S assay. Front Immunol 2022; 13:1002576.
  • Bosheva M, et al. A phase 3, randomized, investigator-blinded trial comparing ceftobiprole with a standard-of-care cephalosporin, with or without vancomycin, for the treatment of pneumonia in pediatric patients. Pediatr Infect Dis 2021; 40: e222-9.
  • Overcash JS, et al.  Ceftobiprole compared with vancomycin plus aztreonam in the treatment of acute bacterial skin and skin structure infections: Results of a Phase 3, randomized, double-blind trial (TARGET). Clin Infect Dis 2021; 73: e1507-17.
  • Welte T, et al. Efficacy and safety of ceftobiprole in patients aged 65 years or older: a post hoc analysis of three Phase III studies. Future Microbiol 2021; 16:543-555.
  • Hamed K, et al. Ceftobiprole versus daptomycin in Staphylococcus aureus bacteremia: a novel protocol for a double-blind, Phase III trial.  Future Microbiol 2020; 15:35-48.
  • Hamed K, et al.  No evidence for ceftobiprole-induced immune hemolytic anemia in three Phase 3 clinical trials. Infect Drug Resist 2020; 13:3461.
  • Stemler J, et al. Mucormycosis in the Middle East and North Africa: Analysis of the FungiScope® registry and cases from the literature. Mycoses 2020; 63:1060-68.
OTHER
  • Backer V et al. Global Airways: A Danish nationwide real-life registry of biologic therapy for chronic rhinosinusitis with nasal polyps. Front Allergy. Manuscript accepted for publication. 
  • Backer V, et al. Real-life evaluation of the effectiveness of biologics for chronic rhinosinusitis with nasal polyps in Europe: a Delphi study to define key variables for the INVENT registry. Front Allergy 2025;6:1680703.
  • Xia W, et al. A 13-week oral toxicity and toxicokinetic study of cannabidiol in Sprague Dawley rats with a 4-week recovery period. Drug Chem Toxicol 2025;13:1-14.
  • Castro D, et al. Transition of patients with Duchenne muscular dystrophy from paediatric to adult care: an international Delphi consensus study. Eur J Paediatr Neurol 2025; 54:130–9.
  • Hamada I, et al. Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex. J Dermatol 2024; 51:752-8.
  • Zhou J, et al. Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study. J Headache Pain 2023; 24:103.
  • Abukhaled M, et al. Case report: Aromatic L-amino acid decarboxylase deficiency in three patient cases from the Kingdom of Saudi Arabia. Eur J Pediatr 2023; 182:2535-2545.
  • Abukhaled M, et al. Aromatic L-amino acid decarboxylase deficiency in countries in the Middle East: a case series and literature review. Front Pediatr 2023; 10:1016239.
  • Alho H, et al. Opioid-related deaths in Europe: Strategies for a comprehensive approach to address a major public health concern. Int J Drug Policy 2020; 76:102616.
  • Kakko J, et al. Craving in opioid use disorder: From neurobiology to clinical practice. Front Psychiatry 2019; 10:592.
  • Chin KM, et al. Association of N-terminal pro brain natriuretic peptide and long-term outcome in patients with pulmonary arterial hypertension. Circulation 2019; 139:2440-50.
  • Torbicki A, et al. Integrating data from randomized controlled trials and observational studies to assess survival in rare diseases. Circ Cardiovasc Qual Outcomes 2019; 12:e005095.
  • Berger RMF, et al. A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3. Br J Clin Pharmacol 2017; 83:1734-44.